BioSpace News Archive

Business

MedPharm, Ltd. Appoints Lynn Allen as Chief Executive Officer

MedPharm, a global topical and transdermal CDMO, announced that Lynn Allen has been named Chief Executive Officer, effective January 1, 2024.

January 18, 2024
·
2 min read
Deals

Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization

Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.

January 18, 2024
·
2 min read
BioMidwest

Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Tempus, a leader in artificial intelligence and precision medicine, announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.

January 18, 2024
·
3 min read
Drug Development

ALK completes first part of phase 1 trial with peanut SLIT-tablet

ALK (ALKB:DC / OMX: ALK B / AKBLF) announced today that it has completed the first part of its phase 1 clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy.

January 18, 2024
·
3 min read
Business

ACGME President and Chief Executive Officer Thomas J. Nasca, MD, MACP Announces Transition

ACGME President and Chief Executive Officer Thomas J. Nasca, MD, MACP announced yesterday that he intends to step down from his current role on January 1, 2025, to establish the ACGME Center for Professionalism and the Future of Medicine.

January 18, 2024
·
4 min read
Drug Development

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Deciphera Pharmaceuticals, Inc. today announced the presentation of new long-term results from the INTRIGUE Phase 3 clinical study comparing QINLOCK® (ripretinib) versus sunitinib in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib.

January 18, 2024
·
10 min read
Biotech Beach

Helio Genomics Collaborates with University of California, Irvine, to Study Effectiveness of Multimodal Epigenetic Sequencing for Enhancing Early Cancer Detection

Helio Genomics today announced that results from an important new research study have been published in the peer-reviewed journal, Genome Medicine.

January 18, 2024
·
4 min read
Business

Celularity Releases CEO Letter to Shareholders

Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder.

January 18, 2024
·
8 min read
Policy

NBME Revitalizes Grants Program to Enhance Assessment in Latin AmericaNBME® Latin America Grants Program Supports Collaboration, Innovation and Sustainability

NBME renews the Latin America Grants Program to continue its commitment to advancing innovative approaches to medical education and enriching the evaluation of health professionals.

January 18, 2024
·
7 min read
Genetown

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

PHAXIAM Therapeutics announces its cash position as of December 31, 2023, and its financial calendar for 2024.

January 18, 2024
·
4 min read